Currently Viewing:
Newsroom
Currently Reading
Average Profit Margin on Oncology Drugs For 340B Hospitals Nears 50%
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro
Conceptual Paper Proposes Four Cost-Reducing Interventions for In Vitro Diagnostics
December 13, 2017 – Kelly Davio

Report Discusses Trends of Psoriasis and Progress of the Global Psoriasis Atlas

Alison Rodriguez
Psoriasis has a significant presence, affecting about 125 million people globally, but current estimates are fragmented because of a lack of a global standard. A new report suggested that global data will need a standardized approach of collection and analysis in order for more accurate estimates of psoriasisí presence.
Psoriasis has a significant presence, affecting about 125 million people globally, but current estimates are fragmented because of a lack of a global standard. A new report suggested that global data will need a standardized approach of collection and analysis in order for more accurate estimates of psoriasis’ presence.

The scientific report “Global State of Psoriasis Epidemiology: A Workshop Report” discusses the trends of psoriasis epidemiology and the progress of the web-based Global Psoriasis Atlas (GPA). It was curated after a workshop by the International Psoriasis Council (IPC) that consisted of global psoriasis experts. The main purpose of the workshop was to assess the current state of psoriasis epidemiology and GPA through a facilitated discussion on the overall health burden of psoriasis on the patient.

Darren Ashcroft, PhD, BPharm, MS, professor at the University of Manchester, emphasized the need for attention of the psoriasis health burden at the patient level. He also expressed the importance of analyzing genetic and environmental factors to determine their associations with cardiovascular disease.

"The data collected by the GPA will demonstrate to healthcare providers and policymakers around the world that psoriasis is not an inconsequential condition," Christopher Griffiths, MD, FRCP, professor at the University of Manchester, corresponding and first author of the report, IPC immediate past-president and GPA director, said in a statement. "The GPA will be a resource that will help improve treatment and patients' access to care worldwide and to recognize psoriasis as a healthcare priority."

The GPA was a main point of emphasis in the report as it was explained to be a long-term initiative that could provide a common standard for assessing the health burden of psoriasis globally. The GPA was established by the International League of Dermatological Societies and the International Federation of Psoriasis Associations.

The first phase of the GPA is expected to begin this year and will consist of global psoriasis data.  The second phase will establish a standardized method for collecting future data from around the world.

“Ultimately, this resource is expected to drive improvement and equality of healthcare planning for psoriasis globally,” the report concluded.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!